MedTrace Logo

Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms

NCT06268847 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2024-08-21

No results posted yet for this study

Summary

This interventional, double-blind, randomized, placebo-controlled study aims to evaluate the effect of a marine by-product hydrolysate supplementation on the reduction of atopic dermatitis symptoms.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product. 2 capsules per day for 90 days of placebo.

DIETARY_SUPPLEMENT

ACT01

2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.

DIETARY_SUPPLEMENT

ACT02

2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.

Sponsors & Collaborators

  • Eurofins

    collaborator INDUSTRY

  • Abyss Ingredients

    lead INDUSTRY

Principal Investigators

  • Frederic DEMILLIERE, MD · Dermscan - Eurofins

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-09
Primary Completion
2024-04-02
Completion
2024-07-03

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06268847 on ClinicalTrials.gov